Speech by Federal Chancellor Dr. Angela Merkel during her visit to Roche Diagnostics GmbH on May 5, 2014, in Penzberg:

Germany Angela Merkel · Former Chancellor of Germany

5 May 2014 · Visit to Roche Diagnostics GmbH · Roche Diagnostics GmbH, Penzberg, Germany

Context
Merkel visited Roche Diagnostics GmbH in Penzberg on May 5, 2014, to celebrate the company's innovation and Germany's pharmaceutical sector strength.
Main themes
Pharmaceutical innovation, biotechnology and oncology research, structural economic change, research and development investment, Germany as a business location, public-private collaboration, cancer therapy advances, workforce excellence, regional economic development, framework conditions for innovation
Duration
~17 min
59th percentile
Words
2,089
59th percentile
Sentences
116
70th percentile
Readability
52
68th percentile
Grade
10.5
27th percentile
Syntax
2.93
38th percentile
Vocabulary
1.95
5th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 57%55%
  • Social 18%17%
  • Ceremonial 12%11%
  • Institutional 11%10%
  • Geopolitical 3%3%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 3%

116 sentences in 34 paragraphs

Dear Mr. Franz,

dear Mr. Prime Minister, dear Horst Seehofer,

dear State Minister Huml,

dear colleague, dear Alexander Dobrindt, here today as a representative of your constituency – a wonderful constituency, there are many more beautiful constituencies, I also have to do something for my own, but I am happy to be here today –, my esteemed ladies and gentlemen and dear employees here in the hall, but also at all the Roche locations in Germany that may be following us now,

Your company sees itself – so I have been told – as a powerhouse. That is certainly justified. If I can take my small impression here – what I have just seen and been explained – then it shows what standards are set by Roche. But also, what is passionately advanced by the employees is truly impressive. They are well-trained, have an exciting job, and are at many points at the forefront of what is happening in their field worldwide. And then it is also a workplace with the purpose of helping other people in the future. That is a very, very good combination.

What I was able to see here, for example regarding blood cancer therapy, absolutely demonstrates the innovative strength of the company. "Research for the medicine of tomorrow" – under this motto, Roche is doing a lot, especially with regard to common diseases, in this context concerning the common disease of cancer. Efforts are being made to improve the quality of life.

Roche, as a Swiss traditional company – we must admit that – but with great locations in Germany, is among the top five pharmaceutical companies worldwide. When you see how great the competition is, you know that we are well advised to do everything in Europe to have such truly world-leading companies in Europe. You are world-class in the fields of biotechnology, oncology, and in vitro diagnostics. That 14,000 employees in Germany are contributing to this success story is a great message. The 5,000 employees in Penzberg enhance Bavaria and Bavarian qualities. I am pleased that you feel particularly comfortable here. You set the standards of tomorrow and are thus a good showcase for the pharmaceutical location Germany as a whole.

The recent investments show that you have confidence in the locations in Germany, that you believe that more can be done in the coming years. What has been invested here alone since 1998 has already been mentioned several times. It shows how many patients have been helped, but also how things have developed further. I am very pleased that clear investments will also be made in the coming years.

Penzberg is certainly an example of possible change. It is often forgotten that Bavaria was not destined to be at the forefront of economic activity in the 21st century. Thus, this location Penzberg is certainly a textbook example of what can be done – also in clever cooperation of ideas on one side, but also the commitment of a state government on the other side.

Successfully managing structural change also means always thinking about the next and the year after and asking: What framework conditions do we need to create to enable research and development? A region can – this is also a message to the many employees – only remain a home for many, including families, if one participates in the work of the future. This has been achieved here in a very remarkable way.

I just reminded myself during my visit to the development department how interconnected things are. If certain research and development activities no longer take place in Germany, those who develop the machines for these things will also be at a disadvantage. I learned in this context that one not only has close relationships with clinics to bring certain things immediately to patients, to test and further develop them, but that one must also always have a foothold with the suppliers. The chain of collaboration must therefore function really well and sensibly. This also means that such companies absolutely need cooperative employees who continuously establish contacts in all directions.

It is already impressive to see how – in this case, I must mention it, dear Horst Seehofer – in Cologne, thus outside the Bavarian borders, there is a very close collaboration. But I also had the Augsburg Clinic shown to me with a perfect Roche laboratory, so the Bavarian soul should be satisfied again.

What can politics contribute? In 2005, when I became Chancellor, we decided in the first Grand Coalition: We want to gradually achieve the goal we have set for ourselves in Europe, namely to spend three percent of gross domestic product on research and development. We have done that. Here we are in a very research-intensive area. Your percentage figures are of course only reached by a few companies.

The three percent of gross domestic product for research and development are divided in such a way that two-thirds are invested by the economy in research and development, and one-third must be contributed by the federal and state governments. We are pleased that we have now achieved these three percent together with the economy with our share. We must do this, because when the South Korean president was recently my guest, she reported that they spend more than four percent in Korea.

If you take a look at the dynamic developments currently taking place in Asia, then we know that the world is not waiting for us. That is why it is incredibly important that we pool our strengths between the various sectors and between politics and the companies that also set the direction for us.

With our high-tech strategy, which is now to be developed and further refined into a cross-departmental innovation strategy, we have set the right accent. What does the high-tech strategy mean? We have taken about 20 areas of science and research and made a very clear analysis: Where does Germany stand? Where do we need to catch up to the world market? And where are we world-class? We then established in cooperation with the economy and research institutions: Where will investments be made in what way?

We are seeing worldwide that thinking in clusters, that is, combinations of companies, research institutions, and political support, is increasing more and more. Therefore, it is also existential for health research, if we want to remain world-class, that we can really translate this combined thinking into action. That is why we are talking quite a bit about a change to Article 91b of the Basic Law – that regional research centers must collaborate with universities. If this does not happen, research will not create the necessary combination of academic, entrepreneurial, and non-university research institutions.

With all due respect for the Humboldtian idea of education: The research idea in universities must remain strong. It can only do so if there is a clear combination with non-university research. For this, the federal and state governments must also cooperate in a new way.

Health research is a focus in our high-tech strategy. We have already provided 5.5 billion euros for it by 2014. It is then very important that we have good companies and of course also good research institutions that tell us in which areas investments must be made. Health research will be strategically further developed. One of the major focuses is, for example, cancer research, but also research on other common diseases. The corresponding centers have been established.

Of course, the individual fields are interconnected. This means that without biotechnology, there will be no progress in health research. That is why Penzberg is also one of the largest biotechnology centers in Europe. I have heard it is probably the largest biotechnology center in Europe. That is of course a real showcase. As part of the "National Research Strategy Bioeconomy 2030," we are providing an additional 2.4 billion euros for the research and development of biotechnology from the federal side between 2011 and 2016. It will now be important to link this sensibly with the investments you are making in the economic sector.

Moreover, we must ensure that our national German research and development strategy also provides impulses to Brussels, to the European projects. Because there are a number of areas in which we as a single country will no longer be able to reach the world top. The advantage of a European internal market is precisely that we gain a weight that is comparable to the US market.

It is important that there is excellence, that the selection criteria are such that truly world-class work is promoted. I am pleased that we still have many, many points of contact in the health sector, although a critical look shows: The importance of European pharmaceutical research and the European pharmaceutical industry has not increased sufficiently – if I may say so – if one is truly ambitious. That is why Mr. Franz also pointed out that a dialogue with politics is indeed necessary. Because you are engaged in high-risk development in the sense that at the beginning of research it is not at all clear what will come out after ten, twelve, or thirteen years.

When I look at some patent discussions that urge that as much as possible be quickly transferred to the generics sector, that is certainly very important in terms of cost efficiency. We politicians must also ensure that our healthcare system can continue to offer every service to everyone. This means that cost efficiency does play a role. But if we want our own developments, we must also grant the research-based pharmaceutical industry the corresponding consultations.

To that end, I want to make two remarks:

The

first

is that I, as Chancellor, am happy to follow this legitimate concern, and that is why a dialogue with the pharmaceutical industry will take place again. I should not say too much concrete, I have been told, because everything is still in coordination between the departments, but we are working on it. You know the coalition agreement.

The

second

is that I also ask you to be transparent about your progress. We have also experienced that the smallest changes are marketed as total novelties – I am not talking about Roche, but it has happened before –. If politics ever gets this impression – it is very difficult for us to distinguish innovation from innovation – then the risk is very high that you will have more disadvantages in the long term because we will then take measures that may not be appropriate. Therefore, the pharmaceutical location Germany, in this case I also say: Europe – because the Swiss are closely involved in European research development – lives from the fact that we are transparent and can exchange honestly. Because not every politician can become a subject expert on the latest medical development.

Dear employees, I would like to address you in conclusion. You are the ones who make it all possible. Such world-class achievements can only be achieved if one really thinks a lot about it, is enthusiastic about the work, appreciates it, and enjoys it. That cannot be commanded at the push of a button. Either people enjoy and take pleasure in such work or they do not. When you work for other people and the impact in the health sector, you are already at the practical end of what can be researched and developed. This means you often see what direct successes you achieve with your work. Therefore, it is certainly a very fulfilling, very exciting, and interesting job.

I just inquired and learned that there are significantly more applications than apprentices can be accepted, but I am pleased that you have increased the number of apprentices. We need well-trained young people. By the way, there will not be more young people in Germany, but in the coming years, there will initially be fewer. This means that with every person you have already trained, you also strengthen your own company.

We, for our part, want to do everything we can to ensure that the working environment here can continue to be as it is today. This is mainly ensured by the Bavarian state government, but the federal government also wants to do its part.

Thank you very much for allowing us to be here today. All the best to you. Have fun, have energy, and have success. Mr. Franz, I wish you good luck with all the decisions you have to make together with those who lead the company on the German side.